Clinical Trial Update: Lactobacillus Reuteri for Prevention of Necrotizing Enterocolitis in Very Low-birth Weight Infants [Phase 3]

View source ↗

Summary

This document reports the completion of a Phase 3 trial of Lactobacillus reuteri to prevent necrotizing enterocolitis in very low birth weight infants. The stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Necrotizing Enterocolitis

Drugs mentioned

• Lactobacillus reuteri DSM 17938 (Lactobacillus reuteri DSM 17938)

Snippet

Sponsor: Zekai Tahir Burak Women's Health Research and Education Hospital | Conditions: Necrotizing Enterocolitis, Very Low Birth Weight Infants | Phase 3 | Status: COMPLETED